Analyst Price Target is $10.00
▲ +325.53% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Omega Therapeutics in the last 3 months. The average price target is $10.00, with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 325.53% upside from the last price of $2.35.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Omega Therapeutics. This Buy consensus rating has held steady for over two years.
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More
